Navigation Links
Breakthrough for stem cell research

A University of New South Wales (UNSW) researcher based at the Diabetes Transplant Unit (DTU) at Sydney's Prince of Wales Hospital has produced a human embryonic stem cell (hESC) line without the use of any animal products. The breakthrough eliminates the risk of animal-to-human contamination in potential stem cell therapy treatments.

"This is the first hESC line produced in Australia and only the second one in the world, which does not use animals in any way. Our line grows on human fetal fibroblast feeder layer that does not require fetal calf serum," said UNSW Senior Lecturer, Dr Kuldip Sidhu, who was the lead scientist responsible for the creation of the line.

"Other researchers have used animal tissue to keep the hESC alive in the petri dish or as a culture to grow it on," said Dr Sidhu. "Those animal products have the potential to transmit retroviruses in humans, which could have disastrous consequences."

Human embryonic stem cell lines are derived from specialized cells from embryos donated by infertile couples that specifically consented for their excess embryos to be used in stem cell research.

These lines could eventually lead to safer treatments for conditions such as diabetes, Parkinson's disease, spinal cord injury and even breast cancer.

"The new line, named 'Endeavour 1', is only the fifth human embryonic stem cell line to be produced in Australia," said UNSW Professor Bernie Tuch, Director of the DTU. "We now hope to collaborate with other researchers, using this line. We will also make it available to other researchers for their own work."

The National Health and Medical Research Council granted a licence to IVF Australia in collaboration with the DTU at the Prince of Wales Hospital to produce six stem cell lines in November 2004. Seed funding for the project came initially from the Australian Foundation for Diabetes Research, and subsequently from Diabetes Australia.

"Couples who have completed their families often ask us to donate the excess embryos created during their past treatments to research to help others," said Emeritus Professor Doug Saunders, Chair of Research & Development Committee, IVF Australia. "We are very encouraged to see the progress of this significant research project."


Source:University of New South Wales

Related biology news :

1. Breakthrough Microarray-based Technology for the Study of Cancer
2. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
3. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
4. Breakthrough isolating embryo-quality stem cells from blood
5. Breakthrough System for Understanding Ocean Plant Life Announced
6. Breakthrough: Scientists create worlds tiniest organic particles
7. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
8. Sciences Breakthrough of the Year: Watching evolution in action
9. Breakthrough in understanding type-2 diabetes as key genes identified
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. HIV vaccine trial breaks ground for future research
Post Your Comments:

(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: